Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Firebrick Pharma Limited ( (AU:FRE) ) is now available.
Firebrick Pharma Limited has taken significant steps to expand the sales of its Nasodine® Nasal Spray in Singapore during the December 2024 quarter. The company signed a Marketing Representation Agreement with Innorini Life Sciences for promotion and sampling, and a deal with Guardian Health & Beauty to sell Nasodine through its pharmacies, supported by a distribution agreement with DKSH Singapore. These initiatives culminated in the distribution of Nasodine stocks to Guardian pharmacies in January 2025. Financially, Firebrick reported a cash balance of $0.91 million at the end of December 2024, with a net cash outflow partially offset by capital raising activities.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical innovator focused on developing and commercializing novel formulations and uses of povidone-iodine (PVP-I). The company has developed Nasodine® Nasal Spray, which contains 0.5% PVP-I, and is expanding its market presence with recent introductions in the United States and Singapore.
YTD Price Performance: 1.67%
Average Trading Volume: 56,133
Technical Sentiment Consensus Rating: Buy
For an in-depth examination of FRE stock, go to TipRanks’ Stock Analysis page.
